UPDATED May 16, 2024
Companys with strong funding and high growth potential
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
BOVN.F | kr4.70 | 0% | n/a | kr2.7b | kr12.58 | PS9.2x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
SGEN | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
0A8R | US$228.95 | 4.6% | 81.1% | US$43.2b | US$229.12 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
IMGN | US$31.23 | 6.6% | 617.9% | US$8.4b | US$28.95 | PS29.1x | E45.8% | n/a | Pharmaceuticals & Biotech | ||
IPHY.F | €2.20 | 0% | -24.9% | €189.2m | €5.87 | PS3.1x | E33.0% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$2.45 | 1.2% | 96.0% | US$293.3m | US$9.23 | PB1.6x | E69.8% | n/a | Pharmaceuticals & Biotech | ||
0A8K | US$31.24 | 6.4% | 658.3% | US$8.4b | US$29.16 | PS29.1x | E45.9% | n/a | Pharmaceuticals & Biotech | ||
ARDX | US$7.79 | 0.3% | 119.4% | US$1.8b | US$13.83 | PS11.5x | E60.7% | n/a | Pharmaceuticals & Biotech | ||
0EVI | €2.34 | 2.3% | -13.9% | €189.2m | €6.28 | PS3.1x | E33.0% | n/a | Pharmaceuticals & Biotech | ||
IPHA | €2.57 | 2.7% | -10.8% | €189.2m | €6.90 | PS3.1x | E33.0% | n/a | Pharmaceuticals & Biotech | ||
ISEE | US$39.95 | 0.9% | 236.3% | US$5.5b | US$40.00 | PB11.6x | E59.0% | n/a | Pharmaceuticals & Biotech | ||
RCEL | US$7.92 | -9.1% | -33.1% | US$211.6m | US$23.24 | PS4x | E60.2% | n/a | Pharmaceuticals & Biotech | ||
SLNO | US$45.66 | -4.2% | 943.7% | US$1.6b | US$68.14 | PB11.6x | E61.5% | n/a | Pharmaceuticals & Biotech | ||
MDGL | US$217.17 | 5.0% | -21.5% | US$4.5b | US$363.86 | PB5.4x | E64.3% | n/a | Pharmaceuticals & Biotech | ||
GTHX | US$4.68 | -6.0% | 68.3% | US$245.2m | US$8.50 | PS2.9x | E48.3% | n/a | Pharmaceuticals & Biotech | ||
TVTX | US$6.69 | 1.4% | -59.7% | US$517.7m | US$14.86 | PS3.3x | E67.7% | n/a | Pharmaceuticals & Biotech | ||
MGTX | US$5.68 | 11.4% | -25.8% | US$355.6m | US$21.20 | PS32.1x | E56.1% | n/a | Pharmaceuticals & Biotech | ||
CSPH.F | HK$0.12 | 0% | n/a | HK$1.6b | n/a | PS3.2x | E56.9% | n/a | Pharmaceuticals & Biotech | ||
ACAD | US$14.85 | -2.4% | -36.0% | US$2.5b | US$27.16 | PS3x | E40.8% | n/a | Pharmaceuticals & Biotech | ||
CLRB | US$3.33 | 8.5% | 108.1% | US$119.4m | US$15.00 | PB13.1x | E64.6% | n/a | Pharmaceuticals & Biotech | ||
CAPR | US$5.64 | 6.4% | 25.3% | US$177.7m | US$21.25 | PS6.6x | E63.1% | n/a | Pharmaceuticals & Biotech | ||
ALDX | US$4.09 | 3.8% | -57.6% | US$247.8m | US$9.25 | PB2.1x | E61.1% | n/a | Pharmaceuticals & Biotech | ||
SPRY | US$9.10 | 3.4% | 17.4% | US$860.4m | US$19.00 | PS88174.7x | E58.7% | n/a | Pharmaceuticals & Biotech | ||
MSB | AU$1.08 | 1.4% | -4.0% | AU$1.2b | AU$1.09 | PS110.3x | E56.8% | n/a | Pharmaceuticals & Biotech |